Holen Sie sich die Stockscreener-App
2.66
0.75%
-0.02
Handel nachbörslich:
2.66
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Aytu BioPharma amends warrants to address accounting classification - investing.com
Aytu BioPharma amends warrants to address accounting classification By Investing.com - Investing.com Canada
Aytu BioPharma Amends Investor Warrants to Restore Equity Classification and Reduce Liabilities - TradingView
Aytu BioPharma (NASDAQ: AYTU) rewrites warrant terms to restore equity - stocktitan.net
Aytu BioPharma Inc (AY20.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
AYTU PE Ratio & Valuation, Is AYTU Overvalued - Intellectia AI
What analysts say about Aytu BioPharma Inc stock2026 Support & Resistance & Weekly Top Stock Performers List - baoquankhu1.vn
AYTU Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Big Picture: Will Aytu BioPharma Inc benefit from rising consumer demandDip Buying & Stepwise Trade Signal Guides - baoquankhu1.vn
If You Invested $1,000 in Aytu Biopharma Inc (AYTU) - stocktitan.net
History Review: What hedge funds are buying Aytu BioPharma Inc2026 Price Momentum & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Aytu BioPharma : Corporate Presentation March 2026 View Presentation Investor Day January 2026 View Presentation - marketscreener.com
Bull Run: Will Aytu BioPharma Inc benefit from rising consumer demand2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Aytu BioPharma, Inc. (AYTU) Competitors - Meyka
Will Aytu BioPharma Inc. stock deliver consistent dividendsJuly 2025 Levels & Consistent Growth Stock Picks - Naître et grandir
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
AYTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aytu BioPharma AYTU Q2 2026 Earnings Transcript - AOL.com
Is Aytu BioPharma Inc. forming a double bottomGlobal Markets & Intraday High Probability Alerts - mfd.ru
Is Aytu BioPharma Inc. stock a good pick for beginnersJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - mfd.ru
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lytton, foundation report 9.99% Aytu BioPharma (AYTU) stake - Stock Titan
What is the cash position of Aytu BioPharma Inc.2025 Trading Recap & AI Forecasted Entry and Exit Points - mfd.ru
Panic Selling: What analysts say about Aytu BioPharma Inc stockMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
Breakouts Watch: What analysts say about Aytu BioPharma Inc stockMarket Risk Summary & High Accuracy Investment Signals - baoquankhu1.vn
Pharma News: Is Aytu BioPharma Inc. (AY20) stock testing key support2025 Trading Recap & Long-Term Capital Growth Strategies - mfd.ru
Will Aytu BioPharma Inc. (AY20) stock benefit from infrastructure billRisk Management & Consistent Growth Stock Picks - mfd.ru
Is Aytu BioPharma Inc. a strong candidate for buy and hold2025 Macro Impact & Short-Term High Return Ideas - mfd.ru
How Aytu BioPharma Inc. (AY20) stock gains from tech spendingGlobal Markets & Advanced Technical Analysis Signals - mfd.ru
Will Aytu BioPharma Inc. outperform tech stocksShare Buyback & Smart Allocation Stock Tips - mfd.ru
Will Aytu BioPharma Inc. benefit from rising consumer demandJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - mfd.ru
Lake Street Remains a Buy on Aytu BioScience (AYTU) - The Globe and Mail
Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - simplywall.st
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance
Aytu BioPharma Q2 Earnings Call Highlights - Defense World
Full Transcript: Aytu BioPharma Q2 2026 Earnings Call - Benzinga
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navi - GuruFocus
Earnings call transcript: Aytu BioPharma Q2 2026 sees revenue dip, stock falls - Investing.com Nigeria
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs - ChartMill
AYTU: Exxua launch drives early momentum; net revenue $15.2M, net loss $10.6M on launch costs - TradingView
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
AYTU Reports Q2 Revenue Decline Amid Shift to New Product Launch - GuruFocus
Aytu BioPharma Q2 Earnings Summary & Key Takeaways - Benzinga
Aytu BioPharma Q2 Earnings Assessment - Benzinga
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - ACCESS Newswire
Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Res - GuruFocus
New Strong Sell Stocks for February 2nd - Nasdaq
Earnings Recap: Is Aytu BioPharma Inc stock influenced by commodity pricesProduct Launch & Weekly Market Pulse Alerts - baoquankhu1.vn
Gainers Report: Will Aytu BioPharma Inc stock benefit from M A2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire
Pharma News: Will Aytu BioPharma Inc benefit from rising consumer demandQuarterly Market Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com South Africa
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire
Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):